{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:56:10Z","timestamp":1788216970607,"version":"build-2803163510"},"reference-count":39,"publisher":"The Journal of Rheumatology","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To provide information on pregnancy outcomes in women receiving certolizumab pegol (CZP).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>The UCB Pharma safety database was searched for pregnancies through to September 1, 2014. Reports for maternal and paternal CZP exposure were included and outcomes examined, and data on CZP exposure, pregnancy, comorbidities, and infant events were extracted by 2 independent reviewers. Concomitant medications and disease activity were reviewed for clinical trial patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Of 625 reported pregnancies, 372 (59.5%) had known outcomes. Paternal exposure pregnancies (n = 33) reported 27 live births, 4 miscarriages, 1 induced abortion, and 1 stillbirth. Maternal exposure pregnancies (n = 339) reported 254 live births, 52 miscarriages, 32 induced abortions, and 1 stillbirth. Almost all reported pregnancies had exposure to CZP in the first trimester, when organogenesis takes place, and a third of them continued the drug into the second and\/or third trimesters. The most frequent indications for maternal CZP use were Crohn disease (192\/339) and rheumatic diseases (118\/339). Twelve cases of congenital malformation and a single neonatal death were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Analysis of pregnancy outcomes after exposure to CZP supports previous reports, suggesting a lack of harmful effect of maternal CZP exposure on pregnancy outcomes. However, additional data from a larger number of outcomes after exposure and studies including an unexposed comparison group are required to fully evaluate CZP safety and tolerability in pregnancy.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.140189","type":"journal-article","created":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T20:09:41Z","timestamp":1446408581000},"page":"2270-2278","source":"Crossref","is-referenced-by-count":73,"title":["Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol"],"prefix":"10.3899","volume":"42","author":[{"given":"Megan E.B.","family":"Clowse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas C.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"F\u00f6rger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Cush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Golembesky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"De Cuyper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2015,11,1]]},"reference":[{"key":"2018112909350716000_42.12.2270.1","doi-asserted-by":"publisher","DOI":"10.1080\/14767050410001668662"},{"key":"2018112909350716000_42.12.2270.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24914"},{"key":"2018112909350716000_42.12.2270.3","first-page":"1595","article-title":"Crohn\u2019s disease as a risk factor for the outcome of pregnancy","volume":"47","author":"Morales","year":"2000","journal-title":"Hepatogastroenterology"},{"key":"2018112909350716000_42.12.2270.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01355.x"},{"key":"2018112909350716000_42.12.2270.5","first-page":"9","article-title":"High rate of preterm birth in pregnancies complicated by rheumatoid arthritis","volume":"31","author":"Langen","year":"2014","journal-title":"Am J Perinatol"},{"key":"2018112909350716000_42.12.2270.6","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.103"},{"key":"2018112909350716000_42.12.2270.7","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.171"},{"key":"2018112909350716000_42.12.2270.8","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i17.2591"},{"key":"2018112909350716000_42.12.2270.9","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.1.2.6"},{"key":"2018112909350716000_42.12.2270.10","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.464"},{"key":"2018112909350716000_42.12.2270.11","doi-asserted-by":"publisher","DOI":"10.1586\/eci.12.103"},{"key":"2018112909350716000_42.12.2270.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2013.03.004"},{"key":"2018112909350716000_42.12.2270.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq285"},{"key":"2018112909350716000_42.12.2270.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0378(97)00068-5"},{"issue":"Suppl 3","key":"2018112909350716000_42.12.2270.15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/annrheumdis-2013-eular.1289","article-title":"Investigation into the binding affinity of certolizumab pegol to FcRn and functional consequences for FcRn-mediated transcytosis: Comparison to infliximab, adalimumab and etanercept","volume":"72","author":"Baker","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2018112909350716000_42.12.2270.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.11.011"},{"key":"2018112909350716000_42.12.2270.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.105254"},{"key":"2018112909350716000_42.12.2270.18","first-page":"656","article-title":"Lack of placental transfer and accumulation in milk of an anti-TNF PEGylated Fab\u2019 fragment in rats: P-0030","volume":"13","author":"Brown","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"2018112909350716000_42.12.2270.19","unstructured":"CIMZIA (certolizumab pegol) . Medication guide. [Internet. Accessed September 22, 2015.]. Available from: www.cimzia.com\/assets\/pdf\/MedicationGuide.pdf"},{"key":"2018112909350716000_42.12.2270.20","unstructured":"European Medicines Agency . CIMZIA (certolizumab pegol) EMA summary of product characteristics. [Internet. Accessed September 22, 2015.] Available from: www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001037\/WC500069763.pdf"},{"key":"2018112909350716000_42.12.2270.21","unstructured":"U.S. Department of Health and Human Services . Reviewer guidance: evaluating the risks of drug exposure in human pregnancies. [Internet. Accessed September 17, 2015.] Available from: www.fda.gov\/downloads\/Drugs\/\/Guidances\/ucm071645.pdf"},{"key":"2018112909350716000_42.12.2270.22","unstructured":"National Institute of Health . Pregnancy: condition information. [Internet. Accessed September 22, 2015.] Available from: www.nichd.nih.gov\/health\/topics\/pregnancy\/conditioninfo\/Pages\/default.aspx"},{"key":"2018112909350716000_42.12.2270.23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090563"},{"key":"2018112909350716000_42.12.2270.24","doi-asserted-by":"crossref","first-page":"S-149","DOI":"10.1016\/S0016-5085(12)60561-7","article-title":"PIANO: A 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy","volume":"142","author":"Mahadevan","year":"2012","journal-title":"Gastroenterology"},{"key":"2018112909350716000_42.12.2270.25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel400"},{"key":"2018112909350716000_42.12.2270.26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.140822"},{"key":"2018112909350716000_42.12.2270.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.10.024"},{"issue":"Suppl 10","key":"2018112909350716000_42.12.2270.28","first-page":"1874","article-title":"Pregnancy outcomes in women exposed to adalimumab: an update on the Autoimmune Diseases In Pregnancy Project","volume":"63","author":"Johnson","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2018112909350716000_42.12.2270.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02405.x"},{"key":"2018112909350716000_42.12.2270.30","first-page":"93","article-title":"Intentional etanercept use during pregnancy for maintenance of remission in rheumatoid arthritis","volume":"29","author":"Scioscia","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 10","key":"2018112909350716000_42.12.2270.31","first-page":"2466","article-title":"Pregnancy outcome in women treated with adalimumab for the treatment of rheumatoid arthritis: the OTIS autoimmune diseases in pregnancy project","volume":"64","author":"Chambers","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2018112909350716000_42.12.2270.32","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/13.8.993"},{"key":"2018112909350716000_42.12.2270.33","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfr083"},{"key":"2018112909350716000_42.12.2270.34","unstructured":"EUROmediCAT . European surveillance of congenital anomalies (EUROCAT). [Internet. Accessed September 17, 2015.] Available from: www.eurocat-network.eu\/homepage"},{"key":"2018112909350716000_42.12.2270.35","first-page":"1","article-title":"Update on overall prevalence of major birth defects\u2014Atlanta, Georgia, 1978\u20132005","volume":"57","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2018112909350716000_42.12.2270.36","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2003.20130.x"},{"key":"2018112909350716000_42.12.2270.37","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00000.x"},{"key":"2018112909350716000_42.12.2270.38","doi-asserted-by":"publisher","DOI":"10.1177\/014107689108400612"},{"key":"2018112909350716000_42.12.2270.39","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.120955"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.140189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T14:03:53Z","timestamp":1543500233000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.140189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,1]]},"references-count":39,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,12,1]]},"published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.3899\/jrheum.140189"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.140189","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,1]]}}}